AR055671A1 - Proceso de fabricacion de derivados de quinazolina - Google Patents
Proceso de fabricacion de derivados de quinazolinaInfo
- Publication number
- AR055671A1 AR055671A1 ARP060104320A ARP060104320A AR055671A1 AR 055671 A1 AR055671 A1 AR 055671A1 AR P060104320 A ARP060104320 A AR P060104320A AR P060104320 A ARP060104320 A AR P060104320A AR 055671 A1 AR055671 A1 AR 055671A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- manufacture
- salt
- quinazoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Procesos químicos para la fabricacion de determinados derivados de quinazolina, o sales de éstos aceptables para el uso farmacéutico. Procesos para a fabricacion de determinados intermediarios utiles en la fabricacion de los derivados de quinazolina, y procesos para la fabricacion de los derivados de quinazolina utilizando dichos intermediarios. en particular, la presente se relaciona con procesos químicos e intermediarios utiles en la fabricacion del compuesto 4-(4-bromo-2- fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina. Reivindicacion 22: un proceso para la fabricacion de 7-(1-ter-butoxicarbonil)piperidin-4-ilmetoxi)-4-(4-bromo-2-fluoroanilino)-6-metoxiquinazolina, un compuesto de formula (10) a partir de 7-hidroxi-4-(4-bromo-2-fluoroanilino)-6-metoxiquinazolina, un compuesto de formula (9) caracterizado porque el proceso comprende los siguientes pasos: (l) hacer reaccionar el compuesto de formula (9) con un compuesto de formula (2) en presencia de una base apropiada., para proporcionar un compuesto de formula (10), o una sal de éste; y (m) aislar el compuesto de formula (10): (m-1) agregando agua y permitiendo que ocurra la cristalizacion del compuesto de formula (10), recolectando el compuesto de formula (10) y lavando el compuesto de formula (10) con agua, seguida por un solvente seleccionado entre acetato de etilo, acetato de butilo y acetonitrilo, a una temperatura en el rango de entre 25 y 55°C; o (m-2) agregando agua y un alcohol seleccionado entre metanol, etanol, isopropanol y n-propanol, y permitiendo que ocurra la cristalizacion del compuesto de formula (10), recolectando el compuesto de formula (10), y lavando el compuesto de formula (10) con una mezcla de agua y el alcohol seleccionado entre metanol, etanol, isopropanol y n-propanol, seguido por un solvente seleccionado entre acetato de etilo, acetato de butilo y acetonitrilo, a una temperatura en el rango de entre 25 y 55°C; y luego el compuesto de formula (10), obtenido en forma de base libre, puede convertirse en una forma de sal, y el compuesto de formula (10), obtenido en una forma de sal, puede convertirse en la base libre, o en forma de una sal alternativo, de ser necesario.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0519879.1A GB0519879D0 (en) | 2005-09-30 | 2005-09-30 | Chemical process |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055671A1 true AR055671A1 (es) | 2007-08-29 |
Family
ID=35395001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104320A AR055671A1 (es) | 2005-09-30 | 2006-09-29 | Proceso de fabricacion de derivados de quinazolina |
Country Status (32)
Country | Link |
---|---|
US (8) | US8163926B2 (es) |
EP (2) | EP1943240B1 (es) |
JP (2) | JP5213715B2 (es) |
KR (1) | KR101307641B1 (es) |
CN (3) | CN102503898B (es) |
AR (1) | AR055671A1 (es) |
AT (2) | ATE448218T1 (es) |
AU (1) | AU2006296367B2 (es) |
BR (1) | BRPI0616715A2 (es) |
CA (2) | CA2624045C (es) |
CY (2) | CY1110275T1 (es) |
DE (2) | DE602006010428D1 (es) |
DK (2) | DK1943240T3 (es) |
ES (2) | ES2335435T3 (es) |
GB (1) | GB0519879D0 (es) |
HK (2) | HK1122553A1 (es) |
HR (2) | HRP20100019T1 (es) |
IL (2) | IL190172A (es) |
ME (2) | ME01466B (es) |
MY (2) | MY149834A (es) |
NO (1) | NO342152B1 (es) |
NZ (2) | NZ593930A (es) |
PL (2) | PL2053048T3 (es) |
PT (2) | PT2053048E (es) |
RS (2) | RS51515B (es) |
RU (1) | RU2448102C2 (es) |
SG (1) | SG165416A1 (es) |
SI (2) | SI2053048T1 (es) |
TW (2) | TWI328580B (es) |
UY (1) | UY29824A1 (es) |
WO (1) | WO2007036713A2 (es) |
ZA (1) | ZA200802416B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101607958A (zh) * | 2002-02-01 | 2009-12-23 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
US7851623B2 (en) * | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
EP2404595B1 (de) * | 2011-09-01 | 2015-08-05 | Symrise AG | Verfahren zur Herstellung von Indanon-Derivaten |
AU2013304102B2 (en) * | 2012-08-15 | 2016-09-01 | Glaxo Group Limited | Chemical process |
CN104098544A (zh) * | 2013-04-07 | 2014-10-15 | 浙江九洲药物科技有限公司 | 一种凡德他尼的制备方法 |
CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870083A (en) * | 1987-11-24 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants |
JP2829744B2 (ja) | 1989-05-31 | 1998-12-02 | 川研ファインケミカル株式会社 | ピペリジンカルボン酸類の製造方法 |
WO1992006086A1 (en) | 1990-10-01 | 1992-04-16 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
ATE231505T1 (de) | 1991-03-28 | 2003-02-15 | Eisai Co Ltd | Neue heterocyclische/cyclische amine |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2118117A1 (en) | 1993-02-18 | 1994-08-19 | Shigeki Fujiwara | Adenosine uptake inhibitor |
ATE171446T1 (de) * | 1993-05-26 | 1998-10-15 | Syntex Inc | 1-phenylalkanone als 5-ht4 rezeptor ligande |
DE4326344A1 (de) | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE69504300T2 (de) * | 1994-01-13 | 1999-04-29 | Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire | Gem-bissubstituierte azazyclische tachykinin-antagonisten |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CN1116286C (zh) | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4-苯胺基喹唑啉衍生物 |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
PT1244647E (pt) * | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
ATE468339T1 (de) | 2001-12-20 | 2010-06-15 | Osi Pharm Inc | Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung |
CN101607958A (zh) | 2002-02-01 | 2009-12-23 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
AU2003207291A1 (en) | 2002-02-06 | 2003-09-02 | Ube Industries, Ltd. | Process for producing 4-aminoquinazoline compound |
CA2495487A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
WO2004071397A2 (en) | 2003-02-13 | 2004-08-26 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
CA2531862C (en) | 2003-07-10 | 2011-10-25 | Astrazenca Ab | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
-
2005
- 2005-09-30 GB GBGB0519879.1A patent/GB0519879D0/en not_active Ceased
-
2006
- 2006-09-27 PT PT09152654T patent/PT2053048E/pt unknown
- 2006-09-27 DK DK06794582.4T patent/DK1943240T3/da active
- 2006-09-27 ES ES06794582T patent/ES2335435T3/es active Active
- 2006-09-27 JP JP2008532864A patent/JP5213715B2/ja not_active Expired - Fee Related
- 2006-09-27 NZ NZ593930A patent/NZ593930A/xx not_active IP Right Cessation
- 2006-09-27 ME MEP-2013-21A patent/ME01466B/me unknown
- 2006-09-27 CA CA2624045A patent/CA2624045C/en not_active Expired - Fee Related
- 2006-09-27 EP EP06794582A patent/EP1943240B1/en active Active
- 2006-09-27 MY MYPI2011003076A patent/MY149834A/en unknown
- 2006-09-27 DE DE602006010428T patent/DE602006010428D1/de active Active
- 2006-09-27 SI SI200630816T patent/SI2053048T1/sl unknown
- 2006-09-27 MY MYPI20080855A patent/MY145540A/en unknown
- 2006-09-27 CN CN201110159729.XA patent/CN102503898B/zh active Active
- 2006-09-27 DE DE602006017004T patent/DE602006017004D1/de active Active
- 2006-09-27 AT AT06794582T patent/ATE448218T1/de active
- 2006-09-27 CN CN201110159628.2A patent/CN102503933B/zh active Active
- 2006-09-27 KR KR1020087009317A patent/KR101307641B1/ko active IP Right Grant
- 2006-09-27 DK DK09152654.1T patent/DK2053048T3/da active
- 2006-09-27 AU AU2006296367A patent/AU2006296367B2/en not_active Ceased
- 2006-09-27 CA CA2745829A patent/CA2745829C/en not_active Expired - Fee Related
- 2006-09-27 AT AT09152654T patent/ATE481399T1/de active
- 2006-09-27 SI SI200630524T patent/SI1943240T1/sl unknown
- 2006-09-27 RS RSP-2010/0520A patent/RS51515B/en unknown
- 2006-09-27 ES ES09152654T patent/ES2350513T3/es active Active
- 2006-09-27 US US12/088,680 patent/US8163926B2/en active Active
- 2006-09-27 NZ NZ566566A patent/NZ566566A/en not_active IP Right Cessation
- 2006-09-27 PL PL09152654T patent/PL2053048T3/pl unknown
- 2006-09-27 WO PCT/GB2006/003587 patent/WO2007036713A2/en active Application Filing
- 2006-09-27 SG SG201006940-9A patent/SG165416A1/en unknown
- 2006-09-27 EP EP09152654A patent/EP2053048B8/en active Active
- 2006-09-27 BR BRPI0616715-2A patent/BRPI0616715A2/pt not_active IP Right Cessation
- 2006-09-27 RU RU2008116573/04A patent/RU2448102C2/ru not_active IP Right Cessation
- 2006-09-27 PT PT06794582T patent/PT1943240E/pt unknown
- 2006-09-27 CN CN200680036468XA patent/CN101277948B/zh active Active
- 2006-09-27 RS RSP-2010/0037A patent/RS51263B/sr unknown
- 2006-09-27 ME MEP-2013-51A patent/ME01531B/me unknown
- 2006-09-27 PL PL06794582T patent/PL1943240T3/pl unknown
- 2006-09-29 AR ARP060104320A patent/AR055671A1/es not_active Application Discontinuation
- 2006-09-29 TW TW095136340A patent/TWI328580B/zh not_active IP Right Cessation
- 2006-09-29 TW TW099102690A patent/TWI424991B/zh not_active IP Right Cessation
- 2006-09-29 UY UY29824A patent/UY29824A1/es unknown
-
2008
- 2008-03-11 NO NO20081267A patent/NO342152B1/no not_active IP Right Cessation
- 2008-03-13 IL IL190172A patent/IL190172A/en not_active IP Right Cessation
- 2008-03-14 ZA ZA200802416A patent/ZA200802416B/xx unknown
- 2008-12-15 HK HK08113582.9A patent/HK1122553A1/xx not_active IP Right Cessation
-
2009
- 2009-09-21 HK HK09108619.5A patent/HK1130478A1/xx not_active IP Right Cessation
-
2010
- 2010-01-11 HR HR20100019T patent/HRP20100019T1/hr unknown
- 2010-01-25 CY CY20101100076T patent/CY1110275T1/el unknown
- 2010-11-12 CY CY20101101019T patent/CY1110887T1/el unknown
- 2010-11-16 HR HR20100620T patent/HRP20100620T1/hr unknown
-
2011
- 2011-12-07 US US13/314,034 patent/US8865899B2/en active Active
-
2012
- 2012-11-28 JP JP2012259782A patent/JP5654546B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-21 IL IL227574A patent/IL227574A/en not_active IP Right Cessation
-
2014
- 2014-09-09 US US14/481,302 patent/US20140378684A1/en not_active Abandoned
-
2015
- 2015-07-22 US US14/805,816 patent/US9815816B2/en active Active
-
2017
- 2017-10-27 US US15/796,615 patent/US10344015B2/en active Active
-
2019
- 2019-05-08 US US16/406,246 patent/US20190263782A1/en not_active Abandoned
-
2020
- 2020-11-02 US US17/086,666 patent/US20220033377A1/en not_active Abandoned
-
2023
- 2023-03-07 US US18/118,549 patent/US20240150317A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055671A1 (es) | Proceso de fabricacion de derivados de quinazolina | |
BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
ES2660146T3 (es) | Sales del inhibidor de cdk | |
PE20110100A1 (es) | Procedimiento de preparacion de n-[trans-4-[4-(ciclopropilmetil)-1-piperazinil]ciclohexil]-4-[[(7r)-7-etil-5,6,7,8-tetrahidro-5-metil-8-(1-metiletil)-6-oxo-2-pteridinil]amino]-3-metoxi-benzamida | |
AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
AR062134A1 (es) | Erlotinib cristalino | |
ATE507212T1 (de) | Morpholine als 5ht2c-agonisten | |
AR063449A1 (es) | Proceso quimico para derivados de quinazolina, intermediarios | |
AR049401A1 (es) | Aza-biciclononanos | |
AR064692A1 (es) | Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos | |
PE20090770A1 (es) | Derivados de benzoxazolona | |
RU2009117654A (ru) | Получение азоксистробина | |
US11827605B2 (en) | Isoquinoline compounds and their use in treating AhR imbalance | |
AR057525A1 (es) | Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion | |
AR077301A1 (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b | |
JP2013531058A5 (es) | ||
AR041678A1 (es) | Formas cristalinas de clorhidrato de donepezil | |
MXPA05003695A (es) | Nuevo proceso para la sintesis de compuestos de 1,3-dihidro-2h-3-benzazepin-2-ona, y aplicacion en la sintesis de ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable. | |
UY29801A1 (es) | Derivados de quinazolina, sales farmacéuticamente aceptables de las mismas, composiciones farmacéuticas conteniéndolas, procedimientos de preparación y aplicaciones. | |
AR055837A1 (es) | Procedimientos para la preparacion de alc0holes aminoetoxibencilicos | |
BRPI0808570B8 (pt) | processo para a preparação de inibidores de glyt-1 | |
PE20070326A1 (es) | Procedimiento para la preparacion de compuestos de 1-[ciano(4-hidroxifenil)metil]ciclohexanol | |
AR057147A1 (es) | Procedimientos para preparar compuestos intermedios de heteroaril -amina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |